Analysts expect Veradermics, Inc to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.72 M | 2.25 M | 1.94 M | 20.40 M | |||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.60 M | 1.88 M | 1.71 M | 17.50 M | |||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.66 M | 2.07 M | 1.82 M | 18.95 M |
Analysts expect Veradermics, Inc to report earnings per share of -1.74 for Q4 25, against a range of -1.89 to -1.59. The most recent reported quarter, Q1 26, came in at -1.26, a 90.9% miss against the -0.66 consensus.
| Metric | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | -1.26 | - | - | - | - | - | - | - | ||||||||||||
| High Estimate | -1.59 | -0.61 | -0.55 | -0.54 | -0.33 | -0.48 | -0.33 | -0.39 | 0.03 | ||||||||||||
| Low Estimate | -1.89 | -0.71 | -0.67 | -0.62 | -0.37 | -0.52 | -0.35 | -0.45 | 0.03 | ||||||||||||
| Consensus Estimate | -1.74 | -0.66 | -0.61 | -0.58 | -0.35 | -0.50 | -0.34 | -0.42 | 0.03 |